Form 4: Arcutis Biotherapeutics Executive Sells Shares for Tax
Insider Transaction Report
Arcutis Biotherapeutics' SVP General Counsel and Corporate Secretary, Masaru Matsuda, sold shares to cover tax obligations related to RSU vesting.
Summary
- Masaru Matsuda, SVP General Counsel and Corporate Secretary of Arcutis Biotherapeutics, Inc., reported a sale of common stock.
- The transactions occurred on November 3, 2025.
- A total of 7,165 shares were sold at a weighted average price of $24.7123 per share, with prices ranging from $24.31 to $25.31.
- An additional 43 shares were sold at a weighted average price of $25.3985 per share, with prices ranging from $25.3361 to $25.40.
- The sales were conducted to cover tax withholding obligations associated with the vesting of Restricted Stock Units.
- Following these transactions, Masaru Matsuda beneficially owns 154,026 shares of common stock.
Sentiment
Score: 5
Explanation: The transaction is a routine sale to cover tax obligations related to RSU vesting, which is a neutral event and does not reflect a change in sentiment towards the company's prospects.
Management Comments
- The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine tax-related sale by an executive, not indicative of a change in company fundamentals or executive confidence.
Key Dates
| Date | Description |
|---|---|
| 11/03/2025 | Date of common stock transactions by Masaru Matsuda. |
| 11/05/2025 | Signature date of the Form 4 filing. |
Recommendation
holdThe reported transaction is a standard sale of shares by an executive to satisfy tax withholding obligations upon the vesting of Restricted Stock Units. This is a common and expected event in executive compensation and does not typically signal a change in the company's fundamentals or the executive's long-term confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.
Keywords
Arcutis Biotherapeutics, ARQT, Masaru Matsuda, Form 4, Insider Transaction, Stock Sale, RSU, Tax Withholding, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.